APArianna Portmann-Baracco

Arianna Portmann-Baracco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arianna Portmann-Baracco has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Mayte Bryce-Alberti

    Department of Surgery, Rutgers New Jersey Medical School, Newark, USA

    3 shared publications
  • Roberto Alfonso Accinelli

    Instituto de Investigaciones de la Altura, Universidad Peruana Cayetano Heredia, Lima 15102, Peru

    2 shared publications
  • Camille M. Webb

    Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú

    1 shared publication
  • Carlos Caparo

    Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú

    1 shared publication
  • Carlos Ruiz-Sánchez

    Affiliations Instituto de Investigaciones de la Altura, Universidad Peruana Cayetano Heredia, Lima, Perú, Facultad de Medicina Albero Hurtado, Universidad Peruana Cayetano Heredia, Lima, Perú

    1 shared publication
  • Claudia Nuñez-Mochizaki

    Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú

    1 shared publication

Latest Publications

  • Severe Acute Respiratory Syndrome-Coronavirus-2 Antibody Status at the Time of Delivery and the Risk of Preeclampsia

    by Arianna S. Portmann-Baracco, Rodrigo Gerónimo Alcorta-Proaño, Claudia Nuñez-Mochizaki, Camille M. Webb, Juan Trelles, Carlos Caparo, Mauricio F. La Rosa

    Objective Our objective was to evaluate the association between severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serologic status in immunologically naive patients and the risk of preeclampsia at the time of delivery. Study Design We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1 to September 30, 2020. We recorded maternal medical and obstetric characteristics and SARS-CoV-2 serologic status. Our primary outcome was the incidence of preeclampsia. Antibody testing was performed, and patients were classified into seropositive groups: immunoglobulin (Ig)G + , IgM + , or both IgG+ and IgM + . Bivariate and multivariable analyses were performed. Results We included 275 patients that were negative for SARS-CoV-2 antibodies, and 165 that were positive. Seropositivity was not associated with higher rates of preeclampsia (p = 0.183) or with preeclampsia with severe features (p = 0.916) even after adjusting for maternal age >35, BMI ≥ 30, nulliparity, and previous history of preeclampsia, and type of serologic status. Previous preeclampsia had the greatest association with the development of preeclampsia (odds ratio [OR] = 13.40; 95% confidence interval [CI]: 4.98–36.09; p < 0.05) and with preeclampsia with severe features (OR = 5.46; 95% CI: 1.65–18.02; p < 0.05). Conclusion We found that in an obstetric population, there was no association between SARS-CoV-2 antibody status and the risk of preeclampsia. Key Points

  • Open Access

    Complicaciones cardiovasculares agudas en una población peruana de pacientes oncológicos

    by Germán Valenzuela-Rodríguez, Miguel Lescano-Alva, Mayte Bryce-Alberti, Arianna Portmann-Baracco, Walter Prudencio-León

    Objetivo. Conocer las complicaciones cardiovasculares agudas más frecuentes en una población peruana de pacientes oncológicos. Materiales y métodos. Estudio retrospectivo, descriptivo de pacientes oncológicos atendidos en la Clínica Delgado entre enero de 2014 a diciembre de 2019, de los cuales se seleccionó el subgrupo con los siete cánceres más prevalentes a nivel nacional según la información de Globocan 2018. Adicionalmente, se evaluó la epidemiología de los pacientes con complicaciones cardiovasculares que condicionaron su hospitalización o que se detectaron en ella, ponderándose su riesgo cardiovascular según las escalas de Hermann y SCORE. Resultados. Cuarenta y cuatro pacientes tuvieron complicaciones; 27 (61,4%) se hospitalizaron debido a causas cardiovasculares agudas. La edad promedio de este subgrupo fue 69,88 años (DS 12,77) y 22 (81,5%) fueron mayores de 60 años. Catorce (51,9%) fueron de sexo masculino. De acuerdo con la escala de Hermann, un 33,3% tuvo un riesgo intermedio y 14,9% un riesgo alto o muy alto. De acuerdo con la escala SCORE, 62,97% tuvieron un riesgo intermedio y un 7,40% un riesgo alto. Las complicaciones cardiovasculares agudas más comunes fueron trombosis venosa profunda e infarto cerebral isquémico (66,65%). Un paciente (3,7%) reportó enfermedad cardiovascular previa. Cuatro pacientes (14,8%) tuvieron una evolución fatal durante la hospitalización. El tiempo de hospitalización tuvo una mediana de 5 días (4-10). Conclusiones. Se presentan los casos de complicaciones cardiovasculares agudas en una población de pacientes oncológicos y su riesgo cardiovascular según las puntuaciones de Hermann y SCORE. Las complicaciones más frecuentes fueron la trombosis venosa profunda (48,14%), el infarto cerebral (18,51%) y el infarto de miocardio (14,81%).


  • Open Access

    Diabetes increases the risk of COVID-19 in an altitude dependent manner: An analysis of 1,280,806 Mexican patients

    by Juan Alonso Leon-Abarca, Arianna Portmann-Baracco, Mayte Bryce-Alberti, Carlos Ruiz-Sánchez, Roberto Alfonso Accinelli, Jorge Soliz, Gustavo Francisco Gonzales

    Aims: The objective of this study is to analyze how the impact of Diabetes Mellitus [DM] in patients with COVID-19 varies according to altitudinal gradient.Methods: We obtained 1,280,806 records from adult patients with COVID-19 and DM to analyze the probability of COVID-19, development of COVID-19 pneumonia, hospitalization, intubation, admission to the Intensive Care Unit [ICU] and case-fatality rates [CFR]. Variables were controlled by age, sex and altitude of residence to calculate adjusted prevalence and prevalence ratios.Results: Patients with DM had a 21.8% higher prevalence of COVID-19 and an additional 120.2% higher prevalence of COVID-19 pneumonia. The adjusted prevalence was also higher for these outcomes as well as for hospitalization, intubation and ICU admission. COVID-19 and pneumonia patients with DM had a 97.0% and 19.4% higher CFR, respectively. With increasing altitudes, the probability of being a confirmed COVID-19 case and the development of pneumonia decreased along CFR for patients with and without DM. However, COVID-19 patients with DM were more likely to require intubation when residing at high altitude.Conclusions: The study suggests that patients with DM have a higher probability of being a confirmed COVID-19 case and developing pneumonia. Higher altitude had a protective relationship against SARS-CoV-2 infection; however, it may be associated with more severe cases in patients with and without DM. High altitude decreases CFR for all COVID-19 patients. Our work also shows that women are less affected than men regardless of altitude.


  • Open Access

    Methylprednisolone pulse therapy: An alternative management of severe COVID-19

    by Patricia Merab Sauñe, Mayte Bryce-Alberti, Arianna Sibila Portmann-Baracco, Roberto Alfonso Accinelli